Live Breaking News & Updates on Shenzhen Kangtai Biological Products Co Ltd

Stay updated with breaking news from Shenzhen kangtai biological products co ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Yong Tai signs definitive agreement with China's Shenzhen Kangtai on Covid-19 collaboration

Senator Jaziri Alkaf Abdillah Suffian (left) and Boo during Yong Tai’s virtual signing ceremony.
PETALING JAYA: Yong Tai Bhd has formalised its collaboration with China’s Shenzhen Kangtai Biological Products Co Ltd by entering into a definitive agreement for the Phase III clinical trials and commercialisation of the latter’s Covid-19 vaccine.
This cements the collaboration that was set up with the head of agreement framework signed in December 2020.
Yong Tai CEO Datuk Boo Kuang Loon said the agreement marks another milestone for the group in its foray into the pharmaceutical business and he is confident that the collaboration will bear fruit in the near term based on Shenzhen Kangtai’s track record. ....

Malaysia General , Yong Tai Bhd , Yong Tai , Malaysia National Pharmaceutical Regulatory Authority , China Shenzhen Kangtai Biological Products Co Ltd , Health Ministry , Shenzhen Kangtai Biological Products Co Ltd , Boo Kuang Loon , Shenzhen Kangtai , National Pharmaceutical Regulatory Authority , மலேசியா ஜநரல் , யோங் தை ப்ட் , யோங் தை , மலேசியா தேசிய மருந்து ஒழுங்குமுறை அதிகாரம் , சீனா ஷென்சென் காங்க்டை உயிரியல் ப்ராடக்ட்ஸ் இணை லிமிடெட் , ஆரோக்கியம் அமைச்சகம் , ஷென்சென் காங்க்டை உயிரியல் ப்ராடக்ட்ஸ் இணை லிமிடெட் , பூ குவாங் லூன் , ஷென்சென் காங்க்டை , தேசிய மருந்து ஒழுங்குமுறை அதிகாரம் ,

Worldwide Pneumococcal Vaccine Industry to 2025 - Development of Protein-Based Combination Pneumococcal Vaccines Presents Opportunities

Segments Covered
By Vaccine, Conjugate Vaccines are anticipated to account as the fastest-growing segment during the forecasted period. They are considered to be more robust over polysaccharide ones and hence are more preferred leading to high demand. It also covers a wide age group as it can vaccinate an infant from 6 weeks old to 5years of age and for people over 50 + age groups, reducing asymptomatic delivery of the bacteria, and thus resulting in marked group immunity.
By Product Type, Prevnar-13 is estimated to account for the fastest-growing segment during the forecasted period as it is recommended by the WHO as an efficient vaccine against pneumonia and has therefore been the widely adopted 13-valent PCV vaccines across the world. It has also been used as an essential vaccine for people above 50 age groups. ....

United States , United Kingdom , Sanofi Pasteur , Laura Wood , Glaxosmithkline Plc , Emergent Biosolutions Inc , Merck Co , Distributor Partner Companies , Merck Co Inc , Astellas Pharma Inc , Lg Chem Ltd , Pfizer Inc , Development Of Protein , Porter Five Forces Analysis , Custom Research , Nuron Biotech Inc , Office Hours Call , Research Methodology , Walvax Biotechnology Co Ltd , Company Profiles , E St Office Hours Call , China National Biotec Group , Panacea Biotec , Minhai Biotechnology Corporation , Serum Institute Of India Pvt , Pnuvax Incorporated ,

Still some ways to go for Malaysian companies' vaccine distribution biz to take off

KUALA LUMPUR (Jan 12): Promising developments on the vaccine front have stirred investor interest in companies that venture into vaccine distribution, in hopes they will be in for bumper profits.
However, it is not clear at this juncture just how much or when these companies can cash in, given just the evaluation process alone for a vaccine to be approved for distribution and use in Malaysia will take five phases. The first phase alone which is the checking of the vaccine dossiers or research documents typically takes between 90 and 120 days, according to the Ministry of Health (MoH).
When contacted, property developer Yong Tai Bhd chief executive officer Datuk Wira Boo Kuang Loon said the company expects to bring its Chinese partner s vaccine into Malaysia by the third quarter of this year, at the earliest, on obtaining approval from the MoH s National Pharmaceutical Regulatory Agency (NPRA). Any vaccines or medicines to be imported into Malaysia for use here will req ....

Kuala Lumpur , Yong Tai , New Zealand , Choon Lui , Bintai Kinden , Nugenerex Immuno , Yong Tai Bhd , Kinsel Sdn Bhd , Genting Bhd , Solution Group Bhd , Nusankota Development Sdn Bhd , Bintai Kinden Corp Bhd , Generex Biotechnology Corp , Sports Ltd , My Eg Services Bhd , Kanger International Bhd , Bintai Holdingsm Sdn Bhd , Oncology Inc , Shenzhen Kangtai Biological Products Co Ltd , Moh Ethics Committee , Ministry Of Health Mo , Moh National Pharmaceutical Regulatory Agency , Datuk Wira Boo Kuang Loon , National Pharmaceutical Regulatory Agency , Ethics Committee , Nugenerex Immuno Oncology Inc ,

Factbox-When and which COVID-19 vaccines are likely to be available in Asia

Regulators in Asia are weighing approval for COVID-19 vaccines developed by Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc, but few nations expect to get significant supplies initially. ....

Republic Of , Han I , T Ai Pei , Soult Ukpyolsi , South Korea , Jakarta Raya , Stanley Widianto , Johnson Janssen , Sangmi Cha , Ben Blanchard , Clarence Fernandez , Ruma Paul , Phuong Nguyen , Roxanne Liu , Karen Lema , Christopher Cushing , Miyoung Kim , Astrazeneca Plc , India Serum Institute , Pfizer Inc , Moderna Inc , Novavax Inc , Thomson Reuters Trust Principles , Shionogi Co Ltd , Shanghai Fosun Pharmaceutical Group Co Ltd , China Sinovac Biotech Ltd ,

Top Glove, Hartalega, Techfast, LBS Bina, Censof, Supercomnet, Cymao, Sanichi, Awantec and Yong Tai

KUALA LUMPUR (Jan 6): Based on corporate announcements and news flow today, the following companies may be in focus tomorrow (Jan 7): Top Glove Corp Bhd, Hartalega Holdings Bhd, Techfast Holdings Bhd, LBS Bina Group Bhd, Censof Holdings Bhd, Supercomnet Technologies Bhd, Cymao Holdings Bhd, Sanichi Technology Bhd, AwanBiru Technology Bhd (Awantec) and Yong Tai Bhd.
BlackRock, which holds a 1.61% stake in
Top Glove Corp Bhd, voted against the election of six independent directors at the rubber glove maker s annual general meeting today, as it is of the view that the board had failed in its duty to mitigate the issues of migrant workers health and safety. The six independent directors are Datuk Lim Han Boon, Datuk Noripah Kamso, Datuk Norma Mansor, Tan Sri Rainer Althoff, Sharmila Sekarajasekaran and Lim Andy. ....

Kuala Lumpur , Yong Tai , Datuk Noripah Kamso , Datuk Norma Mansor , Sharmila Sekarajasekaran , Prestariang Bhd , Rainer Althoff , Sdn Bhd , Danaraj Nadarajah , Kuah Choon Ching , Yong Tai Bhd , Censof Holdings Bhd , Bina Group Bhd , Cymao Holdings Bhd , Petroleum Sdn Bhd , Top Glove Corp Bhd , Tiong Nam Logistics Solutions Sdn Bhd , Sanichi Technology Bhd , Hartalega Holdings Bhd , Tiong Nam Logistics Holdings Bhd , Alliance Bhd , Awanbiru Technology Bhd Awantec , Techfast Holdings Bhd , Shenzhen Kangtai Biological Products Co Ltd , Ai Service Provider , Group Bhd ,